A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    OSE Immunotherapeutics
Updated on 22 March 2022
platelet count
monoclonal antibodies
measurable disease
neutrophil count
solid tumour
investigational therapy
squamous cell carcinoma of the head and neck
targeted therapy
ovarian cancer


This trial will be a two steps Phase I clinical study in patients with advanced solid tumors with an escalating phase (Step 1) followed by an expansion phase (Step 2) of BI 765063, a monoclonal antibody (mAb) antagonist to signal regulatory protein alpha (SIRPα) receptor, a myeloid checkpoint inhibitor administered as single agent, and in combination with BI 754091, a mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor.

Condition Solid Tumor, Adult
Treatment BI 754091, BI 765063
Clinical Study IdentifierNCT03990233
SponsorOSE Immunotherapeutics
Last Modified on22 March 2022


Yes No Not Sure

Inclusion Criteria

Signed and dated, written informed consent form (ICF) prior to any trial-specific procedures
Male or female aged ≥ 18 years (no upper limit of age) at the time of ICF signature
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy of at least 3 months
Patients with a SIRPα polymorphism including at least one V1 allele will be selected (i.e., homozygous V1/V1 or heterozygous V1/V2 in separate cohorts in escalation [Step
and only homozygous V1/V1 in expansion cohorts [Step 2]); SIRPα polymorphism will be assessed in blood sampling (patient DNA) in a central laboratory; V1 allele is understood to include V1 and V1-like alleles
In Step 1: Patients with histologically or cytologically documented
advanced/metastatic primary or recurrent malignancies who failed or are not
eligible to standard therapy
In Step 2: Cohort C1: Patients with histologically or cytologically
advanced/metastatic primary or recurrent unresectable documented MSS
colorectal tumors, whose disease relapsed after standard of care and who
received no prior anti-PD-L1 inhibitors
Cohort C2: Patients with histologically or cytologically advanced or
metastatic documented MSS endometrial carcinoma whose disease relapsed after
standard of care and who received no prior anti-PD-L1 inhibitors
Patients with at least one measurable lesion as per RECIST v1.1
Patients must agree to pre- and on-treatment tumor biopsies. Fresh tumor biopsy may come either from the primary tumor or from a metastasis. Cytological material is not accepted. Archival tumor biopsy is acceptable, if done within 4 weeks before the first treatment administration
Biopsy sites should be carefully selected by the investigator so that it is
safe for the patient and subsequent biopsy can be performed at the same
Adequate biological parameters defined as
location; also if possible should be distinct from the measurable lesion
Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
Hemoglobin (Hb) level ≥ 10 g/dL. (without recent red blood cell transfusion within 2 weeks prior to study entry)
Platelet count ≥ 100 x 10^9/L
Total bilirubin level ≤ 1.5 X Upper Limit Normal (ULN), except for patients with Gilbert's syndrome from whom total bilirubin < 3.0 x ULN or direct bilirubin < 1.5 x ULN is authorized
Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN
Serum creatinine ≤ 1.5 ULN; or creatinine clearance > 50 mL/min (Chronic Kidney Disease Epidemiology [CKD-EPI] formula)
INR ≤ 1.5 (except if patient treated with anti-vitamin K); anticoagulation with anti-vitamin K and Low Molecular Weight Heparin [LMWH] is allowed
Prior major treatment-related surgery completed at least 28 days before study drug
In all cohorts
An interval of at least 28 days since the last chemotherapy, approved immunotherapy, biological or investigational therapy, radiation or tyrosine kinase inhibitor (TKI) therapy (sunitinib, sorafenib) must have elapsed before the first study drug administration(s)
And all toxicities related to previous anticancer therapies have resolved to normal value or ≤ to Grade 1 prior to the study treatment administration, except alopecia
Women must not be breastfeeding
Women of childbearing potential (WOCB) must agree to use highly effective methods of contraception (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly), prior to study entry, during the study and for 5 months after the last dose of study drug
Highly effective methods of contraception are defined as one of the following
methods: combined (estrogen and progestogen containing) hormonal contraception
associated with inhibition of ovulation (oral, intravaginal, transdermal)
progestogen-only hormonal contraception associated with inhibition of
ovulation (oral, injectable, implantable), intrauterine device (IUD)
intrauterine hormone-releasing system (IUS), bilateral tubal occlusion
vasectomised partner, sexual abstinence
Male patient with WOCBP partner must be willing to use male contraception (condoms) during the study and until 5 months after last dose of study drug. WOCBP partners of male subjects participating in the study may use hormone based contraceptives as one of the acceptable methods of contraception since they will not be receiving study drug (i.e.; oral hormonal contraception, cap, diaphragm, or sponge with spermicide)
Females of childbearing potential must have a serum negative pregnancy test within 7 days prior to first administration. Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test
Capable of understanding and complying with protocol requirements
Patients must be affiliated to a social security system or an equivalent system

Exclusion Criteria

Patient with active autoimmune disease or a documented history of autoimmune disease, that requires systemic treatment (i.e. corticosteroids or immunosuppressive drugs)
Patient with symptomatic/active central nervous system (CNS) metastases; Patient with previously treated brain metastases are eligible, if there is no evidence of progression for at least 28 days before the first study treatment administration, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period
Other tumor location necessitating an urgent therapeutic intervention (e.g., palliative care, surgery or radiation therapy, such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture)
Presence of other active invasive cancers, other than the one treated in this trial, within 5 years prior to screening
Known severe infusion related reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTCAE v5.0) and patients removed from previous anti-PD-1 or anti-PD-L1 therapy because of a severe or life-threatening immune-related adverse event (irAE) (Grade ≥ 3 NCI-CTCAE v5.0)
Except appropriately treated basal cell carcinoma of the skin, or in situ
Patients receiving systemic treatment with any immunosuppressive medication within one-week prior treatment start; Steroids of max. 10 mg prednisolone equivalent per day are allowed, topical and inhaled steroids are not considered as immunosuppressive
carcinoma of uterine cervix, or other local tumors considered cured by local
Patients with interstitial lung disease or active, non-infectious pneumonitis
Patient with uncontrolled disease-related metabolic disorders (e.g., hypercalcemia, SIADH) or uncontrolled diabetes
Patient with uncontrolled congestive heart failure defined as New York Heart Association (NYHA) class III or IV, uncontrolled hypertension, unstable heart disease (e.g., coronary artery disease with unstable angina or myocardial infarction within 6 months before study treatment administration)
Patient with significant ECG abnormalities defined as any cardiac dysrhythmia (> Grade
(i.e., significant ventricular arrhythmia as persistent ventricular tachycardia and/or ventricular fibrillation; severe conduction disorders as atrio-ventricular block 2 and 3, sino-atrial block) or baseline QT/QTc interval >480 milliseconds (ms)
Except patients with vitiligo, resolved childhood asthma/atopy, alopecia, or
Patient with significant chronic liver disease (e.g., significant fibrosis, known cirrhosis) or active HBV or HCV infection; If HbsAg positive, an effective antiviral treatment to prevent hepatitis B reactivation is recommended
any chronic skin condition that does not require systemic therapy, patients
Patients with known Human Immunodeficiency Virus (HIV) infection or patients with an active infection requiring specific anti-infective therapy until all signs of infection have resolved, and this within 2 weeks prior to the first study treatment administration
with autoimmune-related hypothyroidism on a stable dose of thyroid replacement
Patient whose medical, psychological including alcohol or drug abuse, or surgical conditions are unstable and may affect the study completion and/or compliance and/or the ability to give informed consent
hormone and/or controlled Type 1 diabetes mellitus on a stable insulin regimen
may be eligible
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note